Patents by Inventor Benedikt Oswald

Benedikt Oswald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240254199
    Abstract: The present disclosure relates to mammalian cells (e.g., Chinese Hamster Ovary (CHO) cells) that are modified to reduce or eliminate the expression of certain mammalian cell endogenous products (e.g., host cell proteins and virus-like particles), and methods of using such cells in the production of a recombinant product of interest, e.g., a recombinant protein, a recombinant viral particle, or a recombinant viral vector. These modifications were specifically chosen to generate engineered mammalian host cells with desired traits in several key areas, including improved cell culture performance (e.g., higher viability and product titers), improved product quality (e.g., more consistent and favorable glycosylation; more stable drug product), and decreased burden on purification for removing problematic or undesired endogenous host cell products (e.g., hydrolytic host cell proteins and virus-like particles) during biomanufacturing.
    Type: Application
    Filed: October 18, 2023
    Publication date: August 1, 2024
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Amy Shen, Inn Huam Yuk, Gavin Christian Barnard, Shahram Misaghi, Simon Auslaender, Niels Bauer, Benedikt Oswald
  • Publication number: 20240011066
    Abstract: Herein are reported modified mammalian cells wherein the expression of the MYC gene and one or more of the BAK, BAX, SIRT-1 and ICAM-1 genes has been reduced or eliminated as well as methods for the recombinant production of a heterologous polypeptide using a modified mammalian cell according to the current invention. Further reported are use of the reduction of the expression of the genes for increasing volumetric productivity, increasing cell volume, increasing viability and increasing the possible cultivation time without cell split.
    Type: Application
    Filed: April 19, 2023
    Publication date: January 11, 2024
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Shahram Misaghi, Amy Shen, Inn Huam Yuk, Gavin Christian Barnard, Simon Auslaender, Niels Bauer, Benedikt Oswald
  • Publication number: 20220220509
    Abstract: Herein is reported a method for generating a recombinant mammalian cell expressing a heterologous polypeptide and a method for producing a heterologous polypeptide using said recombinant mammalian cell, wherein in the recombinant cell the expression of the endogenous SIRT-1 gene has been reduced. It has been found that the knockout of the sirtuin-1 gene (SIRT-1) in mammalian cells, e.g. such as CHO cells, improves recombinant productivity and reduces lactate production by the cells. Additionally, it has been found that the viability decline at the end of a fed-batch fermentation is reduced.
    Type: Application
    Filed: December 22, 2021
    Publication date: July 14, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Simon Auslaender, Benedikt Oswald
  • Publication number: 20220154207
    Abstract: Herein is reported a method for generating a recombinant mammalian cell expressing a heterologous polypeptide and a method for producing a heterologous polypeptide using said recombinant mammalian cell, wherein in the recombinant cell the expression of at least the endogenous gene MYC has been reduced. It has been found that the knockout of at least the endogenous gene MYC in mammalian cells, e.g. such as CHO cells, improves recombinant productivity by the cells.
    Type: Application
    Filed: September 23, 2021
    Publication date: May 19, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Simon Auslaender, Benedikt Oswald, Niels Bauer